Due to their cytotoxic activities, many anticancer drugs cause extensive damage to the intestinal mucosa and have antibiotic activities. Here, we show that cisplatin induces significant changes in the repertoire of intestinal commensal bacteria that exacerbate mucosal damage. Restoration of the microbiota through fecal-pellet gavage drives healing of cisplatin-induced intestinal damage.
INTRODUCTION
Platinum derivatives are one of the most commonly used chemotherapies for cancer. Cisplatin is used alone or in combination as a first-line treatment for advanced-stage ovarian, cervical, pancreatic, non-smallcell lung cancer, or head and neck cancer. Due to inhibition of DNA replication, cisplatin is known to have antibiotic effects on both Gramnegative and Gram-positive bacterial strains, including some Bacillus and Escherichia coli. 1 Despite its broad applications, cisplatin induces multiple adverse effects that severely deteriorate the quality of life of cancer patients and even precludes therapeutic continuation. One of such adverse effects, shared with other chemotherapeutic agents, is damage of the intestinal epithelium. The intestinal epithelium is subject to a rapid cell turn-over and proliferation. Cisplatin binds to DNA and forms crosslinks that impair replication. This damage results in loss of integrity in the intestinal mucosa that prevents chemotherapy continuation and causes bacteremia, which can be life-threatening. Damage to the intestinal mucosa is a major cause of infection in cancer patients treated with chemotherapy. 2 Systemic bloodstream infection due to intestinal bacterial translocation is associated with alterations in the repertoire of commensal microorganisms. 3 Thus far, there are no effective measures to prevent chemotherapyinduced intestinal damage. Preclinical attempts using systemic TGF- 4 or IL-11 5 administration with different chemotherapies have shown promise. However, the tumor promoting effect of these cytokines has precluded clinical translation. 6, 7 Here, we describe how cisplatin therapy alters the intestinal microbiota, and that restoration of the prechemotherapy microbiota through fecal gavage accelerates intestinal healing after cisplatinassociated intestinal damage.
MATERIALS AND METHODS

Animals and cell lines
Wild-type C57BL/6 (8-12 week old) were purchased from Charles River (Wilmington, MA, USA). 
Cisplatin treatment and microbiota gavage
We treated mice with i.p. cisplatin at 10 mg/kg diluted in PBS at day 21 of tumor progression. We resuspended 1 fecal pellet in 1 ml of PBS.
Pellets from noncisplatin-treated tumor-bearing mice from the same cohort were used for fecal gavage after resuspension in PBS. 
Microbiota determination
Fecal DNA was purified using PowerFecal DNA Isolation Kit (Mo Bio, San Diego, CA, USA). We performed 16S Tag sequencing using MiSeq 500-cycle chemistry (Illumina, San Diego, CA, USA). Groups of 5 mice were analyzed.
The sequenced 16S reads were analyzed using the QIIME software package 10 and STAR (https://stamps.mbl.edu/index.php/Picrust_ stamp_lab). Reads were removed from the analysis if they did not match the barcode (up to 2 mismatches were allowed) and primer sequence. Operational taxonomic units (OTUs) were created by clustering the reads at 97% identity using UCLUST. 11 Representative sequences from each OTU were aligned using PyNAST, 12 and a phylogenetic tree was inferred using FastTree v. 2.1.3 13 after applying the standard Lane mask for 16S sequences. 14 STAR software was used for the comparisons. Taxonomic assignments were generated by the UCLUST consensus method of QIIME 1.8, using the GreenGenes 16S database v. 13_8. 15 
Antibodies, flow cytometry, ELISA analysis, and immunohistochemistry
We used fluorochrome-conjugated anti-mouse antibodies, as follows:
anti-CD3e (17A2), CD45 (30-F11), CD11b (M1/70), Ly6G (1A8), Ly6C
(HK1.4) (all from Biolegend, San Diego, CA, USA). Live/dead exclusion was done with Zombie Yellow viability probe (Biolegend, San Diego, CA, USA).
Samples were run using a BD LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using FlowJo.
Ileum and cecum samples were paraffin embedded. For staining, they were subjected to antigen retrieval and deparaffinized. Slides were then stained with H&E or fixed with acetone and washed with PBS, and sections blocked using normal goat serum followed by stain- We analyzed IL-6 by ELISA (eBioscience, San Diego, CA, USA), following manufacturer's instructions.
Quantitative real-time PCR
Tissue RNA was isolated from snap-frozen samples by mechanical dis- 
Statistical analysis
Unless noted otherwise, all experiments were repeated at least twice and with similar results. Differences between the means of experimental groups were calculated using Kruskal-Wallis or ANOVA tests. The distribution of each set of data was calculated using the Shapiro Wilks test. Error bars represent standard error of the mean. All statistical analyses were done using Graph Pad Prism 5.0. P < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
To determine the effect of cisplatin administration on the composition of intestinal commensal bacteria, we first treated different cohorts of mice bearing peritoneal ID8-Defb29/Vegf-a ovarian carcinomatosis [16] [17] [18] [19] [20] with different doses of cisplatin. Doses of 20 mg/ml i.p. resulted in >60% mortality (not shown), whereas 10 mg/ml delayed malignant progression without fatal toxicities and was therefore selected for the rest of the study. Under these conditions, the amount of fecal DNA retrieved from cisplatin treated mice was significantly lower compared with that of untreated mice after 48 h (Fig. 1A) . Furthermore, sequencing of 16S rRNA from fecal DNA showed that cisplatin treatment causes measurable dysbiosis.
This was evidenced by significant increases in bacteria of the Bacteroidaceae and Erysipelotrichaceae families, as well as in Bacteroides uniformis (Figs. 1B-1D and Supplemental File 1). In contrast, cisplatin caused a decrease of R. gnavus, a trans-sialidase expressing bacterial strain that acquires nutritional competitive advantage by degrading mucins (Fig. 1E) . 21, 22 To determine whether the administration of intestinal microbiota from untreated tumor-bearing mice could prevent dysbiosis, we gavaged cisplatin-treated mice with either a fecal pellet suspension from pre-treated tumor-bearing mice or PBS, 2 days after cisplatin treatment (experimental scheme shown in Fig. 1F ). As shown in Figs Fig. 2A) , suggesting that the restoration of the pretreatment intestinal microbiota is able to facilitate healing of the intestinal epithelium.
Gavage of R. gnavus cultures also resulted in a trend for beneficial effects on the intestinal mucosa, although not significant ( Fig. 2A and Supplemental Fig. 1A ).
To understand the systemic effects of cisplatin-induced intestinal damage and disruption of the microbiome, we treated different cohorts of mice bearing established ID8-Defb29/Vegf-a peritoneal carcinomatosis with cisplatin, followed by gavage of prechemotherapy fecal pellets, R. gnavus, or PBS. As shown in Fig. 2B , cisplatin treatment induced severe weight loss, which was ameliorated by bacteriotherapy with fecal pellets but not R. gnavus alone. Correspondingly, loss of intestinal integrity resulted in increased translocation of bacterial products to the blood stream in cisplatin-treated mice. In contrast, reversing dysbiosis through fecal gavage (but not through gavage of R. gnavus alone) prevented bacterial translocation from the gastrointestinal tract (Fig. 2C) . Using genus-and strain-specific primers, we detected the presence of Eubacteria, Lactobacillus, Prevotella, and R.
gnavus in the blood of all treated groups, without significant differences associated with the gavage of different products (not shown).
The passage of bacterial products from the gut to the blood stream was associated with corresponding elevations in serum IL-6 levels, which were again significantly ameliorated by fecal gavage (Fig. 2D) . Accordingly, although cisplatin administration induced significant decreases in the myelomonocytic compartment in peripheral blood 24 hrs after treatment, we also found increased levels of (CD45 + To understand the mechanisms whereby commensal bacteria promote the healing of the intestinal mucosa, we focused on the role of the microbiota in the maintenance of the mucus layer, a protective barrier comprised of glycoproteins, trefoil factors, and mucins. 3 Supporting that restoration of the pretreatment repertoire of commensal bacteria after cisplatin treatment promotes mucus secretion, we found that gavage with fecal pellets promoted higher expression of Muc3, both at the mRNA and protein levels (Figs. 3A-3C ). The administration of R. gnavus was also associated with stimulation of Muc3 production at the mRNA level (Fig. 3A) . However, the administration of this bacterial strain, which has mucin-degrading activity, 21 did not result in the accumulation of Muc3 at the protein level in the gut (Figs. 3B and 3C , and
Supplemental Fig. 1C ).
Mucus production has been shown to be regulated by myeloid cells in other tissues. 23 To further understand how replacement of commensal bacteria promotes mucus secretion, we next analyzed the inflammatory infiltrates in the intestinal mucosa after different treatments.
We found that gavage of both fecal pellets and R. gnavus increased the accumulation of CD11b + myeloid cells in the ileum (Figs. 3D and 3E). To understand the contribution of these intestinal myeloid cells to the production of mucus and, subsequently, mucosal healing, we again performed cisplatin treatments followed by oral gavage of fecal materials in the presence versus the absence of Gr1 depleting antibodies. As shown in Fig. 3F , effective depletion of Gr1 + myeloid cells (Supplementary Fig. 1D ) abrogated protection against bacterial translocation in response to fecal pellet gavage. However, IL-6 was not elevated in serum, indicating that Gr1 + myeloid cells are the major source of IL-6 production after cisplatin chemotherapy (Fig. 3G) . Consistent with increased bacterial translocation upon myeloid cell depletion, intestinal healing also disappeared (Fig. 3H) .
Importantly, this was associated with a significant decrease in the total number of microvessels, as determined by CD31 staining (Figs. 3H   and 3I ). Pooled from 3 independent experiments (n = 7-10 mice/group, total; Kruskal-Wallis test; *P < 0.05; **P < 0.01). (C) Q-PCR quantification of the fold-increase of 16S ribosomal subunit DNA in serum, referred to the signal in PBS-treated mice (No CP). Pooled from 3 independent experiments (n = 12-14 mice/group, total; Kruskal-Wallis test; *P < 0.05). (D) Quantification of IL-6 in the serum of mice receiving CisPlatin, CP, or CisPlatin plus fecal gavage, CPFG (t-test; P < 0.05). Pooled from 2 independent experiments (n = 9-10 mice/group, total). (E) Ly6C + CD11b + Ly6G − myelomonocytic cells in the peripheral blood of tumor-bearing-mice 24 h after receiving PBS versus cisplatin (t-test; P < 0.05). (F and G) Ly6G high CD11b + granulocytes mobilized in the peripheral blood of tumor-bearing-mice treated with PBS or cisplatin, followed by PBS or fecal versus R. gnavus gavage (gated on CD11b + cells). Pooled from 4 independent experiments (n = 12-19 mice/group, total; ANOVA test). Bar, 200 m. Kruskal-Wallis test was used for all datasets, with the exception of (G); *P < 0.05; **P < 0.01
Together, these results indicate that the administration of intestinal microbiota from an untreated tumor-bearing mouse is associated with increased mobilization of intestinal myeloid cells. This promotes the production of elements that comprise the mucus layer and the mobilization of myeloid cells to damaged areas, which is associated with enhanced angiogenesis and faster intestinal healing. Importantly, mucus production is independent from myeloid cell mobilization, as MUC3 production was not affected by Gr1 depletion (not shown). Administration of R. gnavus, which is selectively depleted by cisplatin, induces comparable myeloid cell mobilization and Muc3 mRNA up-regulation. However, this mucin-degrading bacterium does not allow the accumulation of Muc3 at the protein level, resulting in decreased protection against mucosal damage.
Overall, our study demonstrates the effectiveness of administering healthy gut microbiota to accelerate healing from cisplatin-associated epithelial damage and unveils a novel intervention to improve patient wellbeing and chemotherapy completion. We found a significant decrease in R. gnavus in cisplatin treated mice, which was restored with fecal gavage. However, although reconstitution of R. gnavus induced a similar myeloid mobilization and Muc3 mRNA up-regulation as fecal gavage, it was not sufficient to explain the full effect of fecal gavage in promoting the healing of the intestinal mucosa. Interestingly, increases in Ruminococcaceae in fecal microbiomes of melanoma patients have been recently associated with better response to immunotherapy, whereas increases in Bacteroidales had the opposite effect. 24 Cisplatin, therefore, appears to promote a microbiome associated with resistance to immunotherapy, although further studies in humans need to clarify this issue.
Cisplatin-associated intestinal damage is an important determinant of chemotherapy dose reduction, delay in treatment or even cessation of the cancer treatment. 2, 25 For the past few years, the importance of the gut microbiota has taken off, and its implications on human health and disease are starting to be understood. Bacteriotherapy is currently being used to treat recurrent C. difficile colitis. 26 For a clinical translation of our results, feces could be collected prechemotherapy for fecal autotransplantation and reconstitution of the microbiota after treatment with cisplatin. Fecal transplant could, therefore, become a feasible and safe approach in the treatment of chemotherapy-associated intestinal damage. (G) ELISA quantification of IL-6 in the serum of the mice in one of these experiments. (H) Representative CD31 staining of the ilea of cisplatintreated mice receiving gavage with fecal pellets plus Gr1 depleting antibodies versus control IgGs in 2 independent experiments (10 mice/group, total). (I) Quantification of the total number of microvessels, as determined through CD31 staining, in the same samples. No CP, PBS; CP, cisplatin; CPFG, cisplatin followed by fecal gavage; CPBG, cisplatin followed by R. gnavus gavage. Kruskal-Wallis test was used for all datasets, with the exception of (E); *P < 0.05; **P < 0. 
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